Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 11/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21384526 | 0.99 | ATF4 (0.50) | ATF4FPR2GRM5RAB9ASMN1; SMN2 | |
| SCHEMBL25961427 | 0.85 | NPC1 (0.43) | ATF4FPR2GRM5RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23294630 | 0.81 | ATF4 (0.54) | ATF4SCN9A | |
| SCHEMBL21390247 | 0.76 | ATF4 (0.59) | ATF4FPR2GRM5 | |
| SCHEMBL5625543 | 0.76 | GRM2 (0.47) | SCN9AMAPT | |
| SCHEMBL25961526 | 0.73 | RAB9A (0.45) | ATF4FPR2GRM5RAB9ASMN1; SMN2 | |
| SCHEMBL23294739 | 0.72 | ATF4 (0.63) | ATF4 | |
| SCHEMBL28433205 | 0.71 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL24225650 | 0.71 | SMYD3 (0.57) | ATF4SCN9A | |
| SCHEMBL740617 | 0.71 | MGAM (0.56) | SMN1; SMN2ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885FPR2 2942/4885GRM5 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.